Wockhardt Ltd

Small Cap

Healthcare Sector

reflects a positive outlook for the share price

reflects a neutral outlook for the share price

reflects a negative outlook for the share price

The analysts information is for reference only and does not\n  represents an investment recommendation.

Analyst recommendation reflect the views of analysts who follow and write research reports.

Company Information is an introduction to the company’s business that details what it sell, how it was founded, what their mission is, how they manufacture or source their products, and why they serve customers.

Wockhardt shares rose over 8% on June 18, reaching an intraday high of Rs 1,867.90. The stock has gained nearly 45% in a month, driven by high trading volumes and investor interest. The company plans to file a new drug application for Zaynich, a breakthrough antibiotic, with expectations for market entry in 2026-27. Wockhardt's Q4FY25 results showed a narrowed net loss and revenue growth, indicating improved operational performance.

Wockhardt Shares Surge Amid Positive Developments - 18 Jun, 2025

Wockhardt Ltd's shares jumped 17% to a 52-week high of ₹1,810.45, driven by strong investor interest and positive financial results, including a 67% YoY EBITDA growth.

Wockhardt Shares Surge to 52-Week High - 11 Jun, 2025

Wockhardt is focusing on a $7 billion market for its antibiotic Zaynich, with USFDA filing expected soon. Additionally, the company plans to double insulin production capacity to meet rising demand.

Wockhardt Targets Growth in Antibiotics and Insulin Markets - 06 Jun, 2025

Wockhardt has filed for regulatory approval of its novel antibiotic Zaynich, aiming for a launch in India and targeting a $7 billion market in the US and Europe. The company reported a narrowing net loss and increased revenue, indicating improved financial health.

Wockhardt Targets $7 Billion Market with Zaynich - 05 Jun, 2025

Wockhardt's MD emphasizes the recommendation of India-made drugs in the UK, while the company aims to increase revenue to Rs 5,000 crore in three years, driven by new high-margin products.

Wockhardt Targets Revenue Growth and UK Market Expansion - 04 Jun, 2025

Wockhardt Ltd reported a narrowed net loss of Rs 45 crore for Q4 FY25, significantly improved from Rs 177 crore last year. Revenue increased by 6% to Rs 743 crore. The company also announced the re-appointment of Akhilesh Krishna Gupta as Independent Director, pending shareholder approval. These developments reflect Wockhardt's recovery efforts and operational improvements, boosting investor confidence.

Wockhardt Narrows Loss and Increases Revenue in Q4 - 29 May, 2025

Price to Earnings Ratio or Price to Earnings Multiple is the ratio of the share price of a stock to its earnings per share (EPS). It provides an indication of whether a stock at its current market price is expensive or cheap.

The price/earnings-to-growth ratio, or the PEG ratio, is a metric that helps investors value a stock by taking into account a company's market price, its earnings, and its future growth prospects.

Enterprise value (EV) is the total value of a company, defined in terms of its financing. It includes both the current share price (market capitalization) and the cost to pay off debt (net debt, or debt minus cash).

Alpha measures the amount that the investment has returned in comparison to the market index or other broad benchmark that it is compared against.

Beta measures a stock's volatility, the degree to which its price fluctuates in relation to the overall stock market. In other words, it gives a sense of the stock's risk compared to that of the greater market.

Dividend yield measures the quantum of earnings by way of total dividends that investors make by investing in that company.

The debt-to-total-assets ratio shows how much of a business is owned by creditors (people it has borrowed money from) compared with how much of the company's assets are owned by shareholders.

Operating cash flow (OCF) is a measure of the amount of cash generated by a company's normal business operations. Operating cash flow indicates whether a company can generate sufficient positive cash flow to maintain and grow its operations.

This widget shows the information about the stock's peers in consideration along with the different data for those peers so that the user can compare the stock with the other similar stock and invest accordingly.

Promoter holding is the amount of share of the company that is owned by the promoters. The promoters are the company's founders, who hold a majority stake in the company's capital.

A foreign institutional investor (FII) is an investor or investment fund investing in a country outside of the one in which it is registered or headquartered.

A mutual fund is a pool of money managed by a professional Fund Manager. It is a trust that collects money from a number of investors who share a common investment objective and invests the same in equities, bonds, money market instruments, and other securities.

Retail investors execute their trades through traditional or online brokerage firms or other types of investment accounts. Retail investors purchase securities for their own personal accounts and often trade in dramatically smaller amounts as compared to institutional investors.

This widget shows the bifurcation of stocks based on the percentage of stake with the different types of shareholders.

This widget will help value the stock based on the Price to Earning ratio of the stock and compare the valuation with the industry value and other similar stocks. It even shows the timeline of the valuation of the stock and its highest and lowest valuation over time.
A Time Series data is provided which compares the historical stock PE with Industry PE over the period of 5 years.

Insights help you understand the recent movement of the company's critical parameters, giving you an overall view of the company.

Foreign Institutions have increased holdings from 6.54% to 6.81% in Mar 2025 quarter

This section gives you an insight into how the FII Holding has changed for the stock over last few quarters.

FII Holding Up

In the last 1 year, WOCKPHARMA has outperformed top 5 stocks with highest market-cap in Pharmaceuticals

This section gives you an insight into why this company has been the best in its industry for the last 1 year.

Best in 1 Year

In the last 1 month, WOCKPHARMA stock has moved up by 31.3%

This section gives you an insight into the price movement of the stock for the last few quarters.

Price Rise

Mutual Funds have increased holdings from 7.13% to 7.56% in Mar 2025 quarter

This section gives you an insight into how the Mutual Funds Holding has changed for the stock over last few quarters.

MF Holding Up

Revenue is up for the last 2 quarters, 729.0 Cr → 758.0 Cr (in ₹), with an average increase of 3.8% per quarter

This section gives you an insight into how the revenue of the company has moved for the last few quarters.

Revenue Rich

In the last 3 years, WOCKPHARMA has outperformed top 5 stocks with highest market-cap in Pharmaceuticals

This section gives you an insight into why this company has been the best in its industry for the last 3 years.

Best in 3 Years

Promoters holdings remained unchanged at 49.09% of holdings in Mar 2025 quarter

This section gives you an insight into how the Promoter Holding has changed for the stock over the last few quarters.

Promoter Holding Unchanged

Retail Investor have decreased holdings from 34.53% to 33.50% in Mar 2025 quarter

This section gives you an insight into how the Retail Investors Holding has changed for the stock over last few quarters.

Retail Holding Down

Netprofit is down for the last 2 quarters, 14.0 Cr → -25.0 Cr (in ₹), with an average decrease of 278.6% per quarter

This section gives you an insight into how the profit for the company has been for the last few quarters.

Profit Down

S&P BSE 250 SmallCap

Nifty MidSmallcap 400

Nifty 500

Nifty Smallcap 250

BSE 500

S&P BSE 400 MidSmallCap

BSE Healthcare

BSE Small-Cap

Tata Small Cap Fund Direct Growth

HSBC Small Cap Fund Fund Direct Growth

Tata Large & Mid Cap Fund Direct Plan Growth

ICICI Prudential ELSS Tax Saver Fund Direct Plan Growth

Invesco India Smallcap Fund Direct Growth

Wockhardt Ltd’s net profit jumped 85.21% since last year same period to ₹-25Cr in the Q4 2024-2025. On a quarterly growth basis, Wockhardt Ltd has generated -278.57% fall in its net profits since last 3-months.

Name	Value	Action
MACD level (12,26)	-2.59	Bullish
CCI (20)	346.79	Bearish
RSI (14)	45.91	Neutral
Momentum (10)	2.7	Bullish
ADI (14)	47.34	Bullish
Ultimate Oscillator (7,14,28)	26.26	Bearish

Name	Value	Action
SMA (20)	1729.98	Bullish
EMA (20)	1730.78	Bearish
VWMA (20)	1729.08	Bullish
SMA (50)	1737.53	Bearish
EMA (50)	1736.41	Bearish
SMA (200)	1751.71	Bearish
EMA (200)	1748.69	Bearish
KAMA (200)	1732.51	Bearish
DEMA (200)	1740.96	Bearish

Wockhardt Ltd (WOCKPHARMA)

Summary

Overall

Oscillators

Moving Averages